Vistin Pharma ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, sales was NOK 287.68 million compared to NOK 275.81 million a year ago. Revenue was NOK 304.85 million compared to NOK 278.62 million a year ago. Net loss was NOK 4.69 million compared to net income of NOK 24.96 million a year ago. Basic loss per share from continuing operations was NOK 0.11 compared to basic earnings per share from continuing operations of NOK 0.56 a year ago. Diluted loss per share from continuing operations was NOK 0.11 compared to diluted earnings per share from continuing operations of NOK 0.56 a year ago.